CXXC5 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL19054826	0.44	7/20
SCHEMBL2701157	0.69	5/20
SCHEMBL2701160	0.69	5/20
Acrylamide (SCHEMBL3714624)	0.42	5/20
Acrylamide (SCHEMBL8498177)	0.42	5/20
SCHEMBL20416125	0.38	5/20
SCHEMBL12018334	0.53	4/20
SCHEMBL12195116	0.52	4/20
SCHEMBL3790649	0.51	4/20
SCHEMBL12987884	0.49	4/20
SCHEMBL12987813	0.49	4/20
SCHEMBL167151	0.47	4/20
SCHEMBL12764449	0.47	4/20
SCHEMBL12988312	0.46	4/20
SCHEMBL3909752	0.45	4/20
SCHEMBL12987942	0.41	4/20
SCHEMBL15948455	0.41	4/20
SCHEMBL16122605	0.39	4/20
SCHEMBL10798217	0.38	4/20
SCHEMBL18746088	0.37	4/20

Clinical trials — most relevant to CXXC5 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Compared the Efficacy and Safety of CDOP Combined With Chidamide and CDOP in de Novo Peripheral T Cell Lymphoma Patients	PHASE3	UNKNOWN
Evaluation of a Cancer Lysate Vaccine and Montanide (Registered Trademark) ISA-51 VG With or Without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung Cancer	PHASE1/PHASE2	SUSPENDED
Safety and Dose Escalation Study of Zinc Supplementation in Critically Ill Children	PHASE1/PHASE2	COMPLETED
SCARFREE-001: Verteporfin for Scar Prevention	PHASE2	NOT_YET_RECRUITING
Study of the Beach Regimen on Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)	PHASE2	ACTIVE_NOT_RECRUITING
Efficacy and Safety Assessment of Oral LBH589 in Adult Patients With Advanced Soft TIssue Sarcoma After Pre-treatment Failure	PHASE2	COMPLETED
Testing the Combination of MLN4924 (Pevonedistat), Carboplatin, and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Who Have Previously Been Treated With Immunotherapy	PHASE2	ACTIVE_NOT_RECRUITING
A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML	PHASE1	COMPLETED
PHF19 Gene Expression and EZH2 Gene Deletion in Acute Myeloid Leukemia	nan	UNKNOWN
Expression of TET1 Gene in Acute Leukaemia	nan	UNKNOWN
Analysis of the Role of AIRE in Autoimmune Neurological Diseases Associated With Autoantibodies	nan	RECRUITING
C-X-C Chemokine Receptor 4 in Chronic Lymphocytic Leukemia	nan	UNKNOWN
Amplification of Zinc Finger Protein 217 Gene in Multiple Myeloma	nan	UNKNOWN
Autophagy in Systemic Lupus Erythematosus	nan	UNKNOWN
Zinc and the Synthesis of Zinc Binding Proteins (Protocol B)	nan	COMPLETED
Gene Expression Variation and Implant Wound Healing Among Smokers and Diabetics	nan	COMPLETED
Study of the Sex Differences in Inflammatory Diseases in Children	nan	UNKNOWN
Immunophenotyping and Xist Gene in AML	nan	UNKNOWN
Depressed AIRE Gene Expression Causes Immune Cell Dysfunction & Autoimmunity in Down Syndrome	nan	COMPLETED
Diaphragmatic Hernia Research & Exploration, Advancing Molecular Science	nan	RECRUITING
The Danish TURNER Cryopreservation Study	nan	RECRUITING
Transcription Factor Runx2 in Necrotic Femoral Head Tissue	nan	COMPLETED
NCF Gene & TNFSF4 in SLE Patients	nan	UNKNOWN
X-chromosome Inactivation, Epigenetics and the Transcriptome	nan	COMPLETED
Study of Tazemetostat in Adults With Follicular Lymphoma Previously Treated With at Least Two Therapies	nan	WITHDRAWN
Gene Mutations and Rescue in Human Congenital Diaphragmatic Hernia	nan	UNKNOWN
EPIgenetics and in Vivo Resistance of Chronic Myeloid Leukemia Stem Cells to Tyrosine Kinase Inhibitors	nan	UNKNOWN
The Etiology and Progression of Brain Tumors	nan	COMPLETED
X-Chromosome Inactivation Status and Premature Ovarian Failure	nan	COMPLETED
Linkage Study in Familial Pulmonary Fibrosis	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a CXXC5 binder may also engage these)

Protein	Name	Similarity
Q32LB3	—	1.000	Q32LB3 →
Q5R7N4	—	1.000	Q5R7N4 →
Q5XIQ3	—	1.000	Q5XIQ3 →
Q91WA4	—	0.998	Q91WA4 →
Q0VFP6	—	0.992	Q0VFP6 →
B4M7J1	—	0.991	B4M7J1 →
Q6YHU8	—	0.991	Q6YHU8 →
Q61329	—	0.991	Q61329 →
Q95JA5	—	0.991	Q95JA5 →
P93755	—	0.991	P93755 →
P05527	—	0.990	P05527 →
Q7TN99	—	0.990	Q7TN99 →
P16376	—	0.990	P16376 →
Q06831	—	0.990	Q06831 →
P46153	—	0.990	P46153 →
O97952	—	0.990	O97952 →
Q9VB11	—	0.990	Q9VB11 →
Q61060	—	0.990	Q61060 →
P78414	—	0.990	P78414 →
Q06945	—	0.990	Q06945 →
Q12946	—	0.990	Q12946 →
P19091	—	0.989	P19091 →
Q28ZA9	—	0.989	Q28ZA9 →
Q9Z1N7	—	0.989	Q9Z1N7 →
Q9W5E0	—	0.989	Q9W5E0 →
Q2VWA4	—	0.989	Q2VWA4 →
Q9VXG1	—	0.989	Q9VXG1 →
Q90XB3	—	0.989	Q90XB3 →
Q9VW27	—	0.989	Q9VW27 →
Q9VQI9	—	0.989	Q9VQI9 →